Objective: The aim of this study was to evaluate the clinical significance of incidental focal uptake of 18 F-fluorodeoxyglucose ( 18 F-FDG) on positron emission tomography/computed tomography (PET/CT) in the prostate glands of cancer patients. Methods: A retrospective review of 3122 consecutive male patients who underwent 18 F-FDG PET/CT studies with an oncologic indication, over the course of four years, was performed. Studies with incidental 18 F-FDG uptake in the prostate gland were further analyzed. Results: Incidental 18 F-FDG uptake in the prostate gland was identified in 65/3122 men (2.1%). Sufficient follow-up data (≥12 months) were available in 53 patients, of whom 11 had a biopsy and 42 had clinical and imaging follow-up. Malignancy was histologically diagnosed in 4 out of 53 patients (7.5%). There was no statistically significant difference in 18 F-FDG uptake values between benign prostate lesions [maximum standardized uptake value (SUV max ) 7.3] and malignant ones (SUV max 7.2, p=0.95). There was a statistically significant difference between the serum prostate specific antigen (PSA) of the benign group (n=24, PSA=2.7 ng/mL) and the malignant group (n=4, PSA=9.2 ng/mL, p<0.001). There was a direct correlation between SUV max and Gleason score. Conclusion: 18 F-FDG positive prostate incidentalomas were detected in 2.1% of oncologic PET/CT scans and of these 7.5% were malignant. SUV max was not useful for distinguishing between benign and malignant incidental prostate lesions. 18 F-FDG avid prostate incidentalomas on PET/CT should prompt a recommendation for obtaining a serum PSA and further investigation if serum PSA is elevated.
Introduction
Since positron emission tomography/computed tomography (PET/CT) was first introduced for the staging and follow-up of various malignancies, PET/CT readers have been faced with the challenge of interpreting foci of increased 18 F-fluorodeoxyglucose ( 18 F-FDG) uptake in unexpected locations. In addition to malignancy, 18 F-FDG uptake has been described in various sites of normal physiologic processes and tracer biodistribution, in benign nodules and masses, and in infectious and inflammatory processes (1, 2, 3) . Increased 18 F-FDG activity in locations not typical for metastatic spread in patients known for malignancy may alternatively represent an unrelated benign process or even a second primary malignancy, thus complicating the interpretation of the PET/CT study. The most common locations of potentially malignant incidental 18 F-FDG uptake reported in the literature include: breast, gastrointestinal system, the prostate, thyroid, adrenal and parotid glands (4, 5, 6, 7, 8, 9, 10) . Locations such as the thyroid, adrenal, and gastrointestinal system have been investigated extensively in the literature, while locations such as the prostate gland continue to confound PET/CT readers. Several studies have investigated the clinical significance of 18 F-FDG positive prostate incidentalomas (11, 12, 13, 14, 15, 16, 17) . The aim of this study was to determine the frequency of unexpected focal uptake of 18 F-FDG on PET/CT in the prostate glands of cancer patients and to detect the proportion of malignant cases within this group. We examined the possibility of using standardized uptake value (SUV max ) to differentiate benign causes of incidental prostate 18 F-FDG uptake from malignant ones. We also examined if serum prostate specific antigen (PSA) values were different in the benign group as compared to the malignant group.
Materials and Methods

Study Design and Patient Population
3122 consecutive male patients who underwent 18 F-FDG PET/CT studies with an oncologic indication over the course of 48 months (from January 1, 2006 to December 31, 2009) were retrospectively reviewed at our institution, a tertiary care academic hospital. The PET/CT reports that made a special reference to focal 18 F-FDG uptake in the prostate gland provided the basis for this study. Sixty-five patients had incidental 18 F-FDG uptake in the prostate gland and represented the study group. Patients with a previous prostate malignancy or prostatectomy (n=3) were excluded from the study. Patients with insufficient follow-up data (<12 months) (n=9) were also excluded from this study. The remaining 53 cases constituted the study group for further assessment of clinical significance of incidental 18 F-FDG uptake in the prostate gland. Positron Emission Tomography/Computed Tomography Imaging 18 F-FDG PET/CT studies were performed on a hybrid PET/ CT scanner (Discovery ST, General Electric Medical Systems, Waukesha, WI, USA), which combines a dedicated, fullring PET scanner with a 16-slice CT scanner. Patients were required to fast for at least 6 hours before the time of their appointment, and waited in a quiet dark room the morning of their scan. Blood glucose levels were recorded immediately prior to 18 F-FDG administration. If the serum glucose level was greater than 11.1 mmol/L (200 mg/dL), the study was rescheduled. A volume of 400 mL of barium sulfate oral contrast was administered, and 8.14 MBq/kg of 18 18 F-fluorodeoksiglukoz, pozitron emisyon tomografisi/ bilgisayarlı tomografi, prostat spesifik antijen additional images of the extremities acquired if needed. CT scan settings were: 140 kVp, 90-110 mA (depending on the body weight), a rotation time of 0.8 s, a table speed of 17 mm per gantry rotation, a pitch of 1.75:1, and a detector row configuration of 16×0.625 mm. For the PET portion of the study, a 2-D acquisition was performed and images were acquired for 4-5 min per bed position (depending on the body weight) up to 5 to 6 total bed positions (depending on the patient's height). The patient was allowed to breathe normally during the PET and CT acquisitions. Data obtained from the CT acquisition were used for attenuation correction and fusion with PET images. The PET data were reconstructed iteratively using ordered subset expectation maximization software provided by the manufacturer (21 subsets, 2 iterations). PET attenuation corrected, PET non-attenuation corrected, CT, and PET/CT fusion images of the whole body were displayed in the transaxial, coronal, and sagittal planes and were reviewed on a dedicated workstation (Xeleris 2.0, GE Healthcare, Waukesha, WI, USA). PET data were also displayed in a rotating maximum intensity projection image.
Interpretation and Analysis of Positron Emission Tomography/Computed Tomography Images
All PET/CT images were interpreted using visualization and semi-quantitative analysis (SUV max corrected for body weight) by two experienced nuclear physicians, independently. Any focal 18 F-FDG uptake in the prostate gland was noted and each nuclear medicine physician measured the SUV max corrected for body weight, using a spherical region of interest at the site of the most intense uptake in the prostate gland.
Diagnosis and Follow-up
Final diagnosis of benign or malignant prostate incidentaloma was based on histologic tissue sampling in 11 of 53 patients. The remaining 42 patients were assessed clinically and/or by serial imaging with magnetic resonance imaging (MRI) or PET/CT. Lesions were considered benign on serial imaging if there was no further evidence of malignancy in the prostate gland or if there was evidence of regression in SUV max by at least 50% in the absence of treatment over a period of at least 12 months. Serum PSA values obtained within 6 months of the PET/CT scan were compared in the benign and malignant groups.
Statistical Analysis
The Mann-Whitney U test was used to determine if there was a significant difference between the mean SUV max values of the benign and malignant groups. The MannWhitney U (two tailed) test was used to detect a significant difference between the serum PSA values of the benign and malignant groups. A p value less than 0.05 was considered to indicate a statistically significant difference. A correlation between Gleason score and SUV max was established using the Spearman's rank correlation coefficient.
Results
The mean age of the study group was 69.3 years (range: 45-87 years). The primary malignant tumors of the cohort and their relative distribution are listed below (Table 1) . Incidental focal 18 F-FDG uptake in the prostate gland was found in 65 of 3122 (2.1%) men scanned consecutively with PET/CT for an oncologic indication. The mean age of patients with benign prostate lesions was 68.8 years as compared to 74.0 years in patients with prostate malignancy. The distribution of abnormal 18 F-FDG prostate uptake in the 53 patients with sufficient follow-up were identified as: peripheral n=37 (69.8%), central n=7 (13.2%), and multifocal or heterogeneous n=9 (17.0%) ( (Figure 1) . The lowest PSA value of the malignant cases was 6.7 ng/mL. The Gleason scores of the malignant prostate incidentalomas correlated directly with SUV max (Spearman's rank coefficient, rho=0.996, p=0.004) (Figure 2 ).
Discussion
In our study, 2.1% of PET/CT scans performed in men with an oncologic indication revealed incidental uptake in the prostate gland, in keeping with previously reported values ranging from 0.6% to 4.5% (11, 12, 13, 14, 15, 16, 17) . However, the incidence of 18 F-FDG positive prostate incidentalomas that have been confirmed to be malignant varies widely in the literature, from 5.4% (11) up to 58.0% (13), making it difficult for the interpreting physician to Several PSA related indices, such as free-to-total PSA ratio (F/T ratio), PSA density (PSAD) and PSA transition zone density (PSATZ) could further improve the differentiation of benign 18 F-FDG positive prostate incidentalomas from malignant ones. These indices appear to improve cancer detection sensitivity and specificity in patients with low serum PSA levels. The ratio of free-to-total PSA (F/T ratio) is known to be reduced in cases of prostate cancer. For patients with PSA levels between 4.0 and 10.0 ng/mL, the recommended cut-off value for F/T is ≤0.25. The ideal cut-off for PSAD is 0.15 ng/mL/cm 3 (26, 27, 28, 29, 30) . These indices may one day play a role in helping determine whether a patient with an 18 F-FDG positive prostate incidentaloma is at high risk for harboring a prostate malignancy and should have a biopsy or whether a biopsy is not necessary. Novel PET/CT agents such as gallium-68 ( 68 Ga)-prostate-specific membrane antigen (PSMA) may also become useful in differentiating benign 18 F-FDG avid prostate incidentalomas from malignant ones, as several studies have recently reported prostate cancer detection rates by 68 Ga-PSMA PET/CT imaging in the range of 90-100% (33, 34, 35) .
Conclusion
In our patient population, 2.1% of 18 F-FDG PET/CT scans performed in men for an oncologic indication revealed incidental 18 F-FDG uptake in the prostate gland. Among those prostate incidentalomas, 7.5% were malignant. SUV max alone was unable to differentiate between benign and malignant prostate lesions, however there was a statistically significant difference between the serum PSA of benign and malignant prostate lesions. These findings suggest that obtaining a serum PSA level in a patient with an 18 F-FDG positive prostate incidentaloma is a reasonable initial course of action. Patients with significantly elevated serum PSA levels can then be investigated further with biopsy, or followed non-invasively with serial PSAs, clinical examination or follow-up imaging.
